COR vs MCK
Cencora and McKesson Corporation, both Healthcare
McKesson Corporation is the larger company at $111B against $62B. On trailing earnings COR is the cheaper of the two at a P/E of 24.1 against 25.6, a gap that is only a bargain if the two are growing at similar rates. Over the past year MCK returned +37% against +13% for COR. The RyuScore puts MCK ahead, 86 against 64 out of 100.
| Figure | COR | MCK |
|---|---|---|
| Last close | $325 | $955 |
| Market cap | $62B | $111B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 24.1 | 25.6 |
| Dividend yield | 0.7% | n/a |
| 1-year return | +13% | +37% |
| 5-year return | +183% | +380% |
| RyuScoresector-relative, 1–10 | 64/100 | 86/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Cencora
Revenue of $85B in Q3 2026, net income $764M. Its largest reported line is US Healthcare Solutions, 92% of the disclosed total.
McKesson Corporation
Revenue of $105B in Q1 2027, net income $614M. Its largest reported line is North American Pharmaceutical, 82% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.